Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T17:16:23.216Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors which can make Patients Difficult to Treat

Published online by Cambridge University Press:  06 August 2018

John M. Kane
John M. Kane*
Affiliation:
Department of Psychiatry, Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, New York, and Albert Einstein College of Medicine, Bronx, New York
Get access Rights & Permissions [Opens in a new window]

Extract

Despite considerable advances in the treatment of schizophrenia, there remains a sizeable subgroup of individuals with this illness who are considered difficult to treat. There are a number of factors which may contribute to this phenomenon and given increasing pressure to reduce health care expenditures, the challenge of managing this patient population is becoming increasingly pressing.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 169 , Issue S31: Management of Difficult to Treat Patients with Schizophrenia , December 1996 , pp. 10 - 14
Copyright
Copyright © 1996 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Breier, A., Buchanan, R. W., Kirkpatrick, B., et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20–26.Google ScholarPubMed
Cole, J. O., Goldberg, S. C. & Davis, J. M. (1966) Drugs in the treatment of psychosis: controlled studies. In Psychiatric Drugs (ed. Solomon, P.), pp. 153–180. New York: Groller and Stratton.Google Scholar
Drake, R. E., McLaughlin, P., Pepper, B., et al (1991) Dual diagnosis of major mental illness and substance abuse disorder: an overview. New Directions in Mental Health Services, 50, 3–12.CrossRefGoogle Scholar
Essock, S. M., Hargreaves, W. A., Dohm, F. A., et al (1996) Clozapine eligibility among state hospital patients. Schizophrenia Bulletin, 22, 15–25.CrossRefGoogle ScholarPubMed
Galanter, M., Castenada, R. & Ferman, J. (1988) Substance abuse among general psychiatric patients: place of presentation, diagnosis and treatment. American Journal of Drug and Alcohol Abuse, 142, 211–235.CrossRefGoogle Scholar
Honigfeld, G., Gillis, R. D. & Klett, C. J. (1966) NOSIE-30: a treatment-sensitive ward behaviour scale. Psychological Reports, 19, 180–182.CrossRefGoogle Scholar
Jeste, D. V. & Caligiuri, M. P. (1993) Tardive dyskinesia. Schizophrenia Bulletin, 19, 303–316.CrossRefGoogle ScholarPubMed
Juarez-Reyes, M. G., Shumway, M., Battle, C., et al (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 76, 801–806.Google Scholar
Kane, J. M. (1985) Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology, 5, 22S–27S.CrossRefGoogle ScholarPubMed
Kane, J. M. (1995) Tardive dykinesia. Presented at the International Congress on Schizophrenia Research Meeting. Warm Springs, Virginia, April 12, 1995.Google Scholar
Kane, J. M., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle Scholar
Kane, J. M., Safferman, A. Z., Pollack, S., et al (1994) Clozapine, negative symptoms and extrapyramidal side effects. Journal of Clinical Psychiatry, 55 (Suppl. B), 74–78.Google ScholarPubMed
Kane, J. M., Marder, S. R., Schooler, N., et al (1995) Efficacy of clozapine vs. haloperidol in a long-term clinical trial. Presented at the American Psychiatric Association Meeting. Miami, Florida, May 24, 1995.Google Scholar
Kinon, B. J., Kane, J. M., Johns, C., et al (1993) Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacology Bulletin, 29, 309–314.Google ScholarPubMed
Levinson, D. F., Simpson, G. M., Singh, H., et al (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry, 47, 761–768.CrossRefGoogle ScholarPubMed
Lieberman, J. A., Jody, D., Alvir, J. M. J., et al (1991) Negative symptoms in schizophrenia: relationship to positive symptoms and outcome. In Negative versus Positive Schizophrenia (eds Marneros, A., Andreasen, N. C. & Tsuang, M. T.), pp. 109–125. Berlin: Springer-Verlag.CrossRefGoogle Scholar
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.Google ScholarPubMed
McEvoy, J. P., Hogarty, G. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739–745.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Regier, D. A., Farmer, M. E., Rae, D. S., et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264, 2511–2518.CrossRefGoogle ScholarPubMed
Remington, G., Pollock, B., Voineskos, G., et al (1993) Acutely psychotic patients receiving high-dose haloperidol therapy. Journal of Clinical Psychopharmacology, 13, 41–45.CrossRefGoogle ScholarPubMed
Rifkin, A., Doddi, S., Karagi, B., et al (1991) Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166–170.CrossRefGoogle ScholarPubMed
Safferman, A. Z., Kane, J. M., Aronowitz, J. S., et al (1994) The use of clozapine in neurologic disorders. Journal of Clinical Psychiatry, 5 (Suppl. B), 98–101.Google Scholar
Shaner, A., Khalsa, M. E., Roberts, L. J., et al (1993) Unrecognized cocaine use among schizophrenic patients. American Journal of Psychiatry, 150, 758–762.Google ScholarPubMed
Siris, S. G., Morgan, V., Fagerstrom, R., et al (1987) Adjunctive imipramine in the treatment of post psychotic depression: a controlled trial. Archives of General Psychiatry, 44, 533–539.CrossRefGoogle Scholar
Terkelsen, K. G. & Grosser, R. C. (1990) Estimating clozapine's cost to the nation. Hospital and Community Psychiatry, 41, 863–869.Google ScholarPubMed
Van Putten, T., Marder, S. R. & Mintz, J. A. (1990) Controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754–758.CrossRefGoogle ScholarPubMed
Yesavage, J. & Zarcone, V. (1993) History of drug abuse and dangerous behaviour in inpatient schizophrenics. Journal of Clinical Psychiatry, 44, 259–261.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.